Advertisement
Advertisement

IMVT

IMVT logo

Immunovant Inc

26.25
USD
-1.66
-5.95%
Dec 18, 15:59 UTC -5
Closed
...

Immunovant Inc Profile

About

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company is developing batoclimabas a fixed-dose subcutaneous injection for the treatment of autoimmune diseases. It's developing batoclimab with an initial focus on the treatment of myasthenia gravis, an autoimmune disease; thyroid eye disease; and warm autoimmune hemolyticanemia. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd. (RSL). Roivant Sciences GmbH (RSG), a wholly-owned subsidiary of RSL, entered into the HanAll agreement. Per the agreement, RSG received the non-exclusive right to manufacture and exclusively develop, import and use batoclimaband commercialize it in the United States, the EU during the term of the agreement.

Info & Links

CEO

Peter Salzmann

Headquarters

320 WEST 37TH STREET
NEW YORK, NY 10018, UNITED STATES

Industry

Biotechnology

Sector

Health Technology

Website

www.immunovant.com

Auditor

Ernst & Young LLP

Share holders

3

Employees

207

Immunovant Inc Statistics

Valuation Measures

Market Capitalization2

3.85B

Enterprise Value

3.38B

Enterprise Value/EBITDA(ttm)

-9.59

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

8.57

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-56.40%

Return on Invested Capital(ttm)

-60.06%

Return on Assets(ttm)

-52.03%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-352.33M

Net Income Available to Common(ttm)

-323.01M

Diluted EPS(ttm)

-2.22

Share Statistics

Beta (5Y Monthly)

0.64

52-Week Change

-35.68%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

146.78M

Dividend Yield

0.00%

Float4

138.13M

% Held by Insiders

5.90%

% Held by Institutions

47.08%

Balance Sheet

Total Cash(mrq)

472.94M

Total Cash Per Share(mrq)

3.22

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

7.61%

Quick Ratio(mrq)

7.61%

Book Value Per Share(mrq)

3.06

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.13

Free Cash Flow(ytd)

-165.22M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement